Incyte Corporation - Common Stock (INCY)
60.34
+0.34 (0.57%)
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for patients with serious diseases, particularly cancer and other unmet medical needs
The company leverages its expertise in molecular biology and drug development to create targeted treatments that aim to improve patient outcomes. With a strong emphasis on research and clinical trials, Incyte strives to advance its pipeline of potential medications, which includes both its proprietary compounds and collaborations with other pharmaceutical partners. Through its commitment to scientific excellence and patient-centric approaches, Incyte aims to address significant healthcare challenges and enhance the quality of life for individuals suffering from complex conditions.
Previous Close | 60.00 |
---|---|
Open | 60.37 |
Bid | 59.20 |
Ask | 61.24 |
Day's Range | 59.92 - 61.15 |
52 Week Range | 50.35 - 83.95 |
Volume | 2,323,185 |
Market Cap | 13.42B |
PE Ratio (TTM) | 301.70 |
EPS (TTM) | 0.2 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,843,868 |
News & Press Releases
Via Benzinga · March 18, 2025
Via Benzinga · March 18, 2025
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.
Via Chartmill · March 17, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.
Via Chartmill · March 17, 2025

Via Benzinga · March 11, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · March 17, 2025
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY)
fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment, which fell below Wall Street's expectations. According to the data, the drug was effective for less than half of the participants who took it in the trials.
Via StockStory · March 17, 2025
Let's have a look at what is happening on the US markets on Monday. Below you can find the S&P500 gap up and gap down stocks in today's session.
Via Chartmill · March 17, 2025
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Via Chartmill · March 17, 2025
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · March 17, 2025
Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and a well-tolerated safety profile.
Via Benzinga · March 17, 2025
Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as shares fell.
Via Investor's Business Daily · March 17, 2025
Via Benzinga · March 17, 2025
Take a closer look at INCYTE CORP , a remarkable value stock. NASDAQ:INCY excels in fundamentals and maintains a very reasonable valuation.
Via Chartmill · March 17, 2025
Via Benzinga · March 17, 2025
Via Benzinga · March 17, 2025
Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).
By Incyte · Via Business Wire · March 17, 2025

Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results comparable to adults at 52 weeks.
Via Benzinga · March 11, 2025

Incyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary endpoint fell short.
Via Benzinga · March 10, 2025

Incyte (Nasdaq:INCY) today announced results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult patients (≥18 years) with prurigo nodularis (PN). The positive TRuE-PN1 data were presented as a late-breaking oral presentation (Session: S028 – Late-Breaking Research: Session 1) today at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando.
By Incyte · Via Business Wire · March 8, 2025

The US market session of Friday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
Via Chartmill · March 7, 2025

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 13,351 shares of the Company’s common stock to 16 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of March 3, 2025, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
By Incyte · Via Business Wire · March 7, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · March 3, 2025

Stay tuned for the market movements in the S&P500 index on Monday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · March 3, 2025

Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando.
By Incyte · Via Business Wire · February 28, 2025